Roche sells off its struggling IL-13 drug lebrikizumab in $1.4B Dermira deal
After watching its late-stage asthma program for its IL-13 drug lebrikizumab flounder with mixed and markedly unimpressive results, Roche is outlicensing the bulk of the development rights to Dermira $DERM in a $1.4 billion deal — which starts off with $135 million in near-term cash.
Dermira is planning to hustle its new drug directly into a Phase IIb study for atopic dermatitis so it can line up a dose as quickly as possible that researchers can take into Phase III.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.